Access to mifepristone, the FDA-approved medication used to end pregnancy, could become severely limited following a ruling from a US appeals court on Friday, which temporarily blocked the drug from being dispensed through the mail.
The decision is for now the most sweeping threat to abortion access since the supreme court rolled back abortion rights in 2022, said Kelly Baden, vice-president at the Guttmacher Institute, an abortion rights advocacy group.
“If allowed to stand, it would severely restrict access to mifepristone in every state, including those where abortion is broadly legal and where voters have acted to protect abortion rights,” she said.
The so-called “abortion pill” is part of a two-drug regimen backed by decades of evidence for its efficacy and safety, and is used in the majority of abortions in the US.
Usage has risen in recent years, especially in the aftermath of the 2022 ruling from the supreme court that overturned federal protections for the right to an abortion. In the year after that decision, the FDA formally modified its regulations to allow the drug to be prescribed online, expanding its use even in states where abortion care was being constricted.
The drug has become a key target for the anti-abortion movement, and a series of lawsuits have challenged the drug’s initial approval in 2000 and the subsequent rules making it easier to obtain.
Meanwhile, with the FDA now under Trump, the agency has opened a review of the medication. Once this analysis is completed, officials at the agency said, they will determine if changes to its regulations are warranted.
Reproductive rights advocates have voiced concerns that the review could further limit mifepristone’s use, despite the evidence supporting its safety.
Source: The Guardian, 4 May 2026
Recommended Comments
Create an account or sign in to comment